22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Neonatal Fc Receptor (FcRn): A Misnomer?

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Antibodies are essential components of an adaptive immune response. Immunoglobulin G (IgG) is the most common type of antibody found in circulation and extracellular fluids. Although IgG alone can directly protect the body from infection through the activities of its antigen binding region, the majority of IgG immune functions are mediated via proteins and receptors expressed by specialized cell subsets that bind to the fragment crystallizable (Fc) region of IgG. Fc gamma (γ) receptors (FcγR) belong to a broad family of proteins that presently include classical membrane-bound surface receptors as well as atypical intracellular receptors and cytoplasmic glycoproteins. Among the atypical FcγRs, the neonatal Fc receptor (FcRn) has increasingly gained notoriety given its intimate influence on IgG biology and its ability to also bind to albumin. FcRn functions as a recycling or transcytosis receptor that is responsible for maintaining IgG and albumin in the circulation, and bidirectionally transporting these two ligands across polarized cellular barriers. More recently, it has been appreciated that FcRn acts as an immune receptor by interacting with and facilitating antigen presentation of peptides derived from IgG immune complexes (IC). Here we review FcRn biology and focus on newer advances including how emerging FcRn-targeted therapies may affect the immune responses to IgG and IgG IC.

          Related collections

          Most cited references229

          • Record: found
          • Abstract: found
          • Article: not found

          Atomic structure and chemistry of human serum albumin.

          The three-dimensional structure of human serum albumin has been determined crystallographically to a resolution of 2.8 A. It comprises three homologous domains that assemble to form a heart-shaped molecule. Each domain is a product of two subdomains that possess common structural motifs. The principal regions of ligand binding to human serum albumin are located in hydrophobic cavities in subdomains IIA and IIIA, which exhibit similar chemistry. The structure explains numerous physical phenomena and should provide insight into future pharmacokinetic and genetically engineered therapeutic applications of serum albumin.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The function of Fcγ receptors in dendritic cells and macrophages.

            Dendritic cells (DCs) and macrophages use various receptors to recognize foreign antigens and to receive feedback control from adaptive immune cells. Although it was long believed that all immunoglobulin Fc receptors are universally expressed by phagocytes, recent findings indicate that only monocyte-derived DCs and macrophages express high levels of activating Fc receptors for IgG (FcγRs), whereas conventional and plasmacytoid DCs express the inhibitory FcγR. In this Review, we discuss how the uptake, processing and presentation of antigens by DCs and macrophages is influenced by FcγR recognition of immunoglobulins and immune complexes in the steady state and during inflammation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Therapeutic antibodies for autoimmunity and inflammation.

              The development of therapeutic antibodies has evolved over the past decade into a mainstay of therapeutic options for patients with autoimmune and inflammatory diseases. Substantial advances in understanding the biology of human diseases have been made and tremendous benefit to patients has been gained with the first generation of therapeutic antibodies. The lessons learnt from these antibodies have provided the foundation for the discovery and development of future therapeutic antibodies. Here we review how key insights obtained from the development of therapeutic antibodies complemented by newer antibody engineering technologies are delivering a second generation of therapeutic antibodies with promise for greater clinical efficacy and safety.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                10 July 2019
                2019
                : 10
                : 1540
                Affiliations
                [1] 1Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital , Boston, MA, United States
                [2] 2Department of Biosciences, University of Oslo , Oslo, Norway
                [3] 3Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Harvard Medical School, Boston Children's Hospital , Boston, MA, United States
                [4] 4Department of Immunology, Oslo University Hospital Rikshospitalet , Oslo, Norway
                [5] 5Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital , Oslo, Norway
                [6] 6Harvard Digestive Diseases Center , Boston, MA, United States
                Author notes

                Edited by: Moncef Zouali, Institut National de la Santé et de la Recherche Médicale (INSERM), France

                Reviewed by: Roberta Bulla, University of Trieste, Italy; Yuri Sykulev, Thomas Jefferson University, United States; Sally Ward, Texas A & M University System, United States

                *Correspondence: Michal Pyzik mpyzik@ 123456bwh.harvard.edu

                This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology

                †These authors have contributed equally to this work

                Article
                10.3389/fimmu.2019.01540
                6636548
                31354709
                9c7769f9-81b4-4574-8dad-a8c6c64d20c3
                Copyright © 2019 Pyzik, Sand, Hubbard, Andersen, Sandlie and Blumberg.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 19 March 2019
                : 20 June 2019
                Page count
                Figures: 5, Tables: 0, Equations: 0, References: 301, Pages: 24, Words: 22536
                Funding
                Funded by: National Institute of Diabetes and Digestive and Kidney Diseases 10.13039/100000062
                Categories
                Immunology
                Review

                Immunology
                igg,igg immune complex (igg-ic),albumin (alb),fcrn,immunity,therapeutic
                Immunology
                igg, igg immune complex (igg-ic), albumin (alb), fcrn, immunity, therapeutic

                Comments

                Comment on this article